Psychotropic medications in autism: Practical considerations for parents

Journal of Autism and Developmental Disorders

Volumn 42, Issue 6, 2012, Pages 1249-1255

  Williamson, Edwin D ^a   Martin, Andres ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autism; Autistic disorder; Disruptive behavior; Parent; Primary care provider

Indexed keywords

AMPHETAMINE; CITALOPRAM; LAMOTRIGINE; LITHIUM; METHYLPHENIDATE; PLACEBO; PSYCHOTROPIC AGENT; RISPERIDONE; VALPROATE SEMISODIUM; VALPROIC ACID;

ADVERSE DRUG REACTION; ARTICLE; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; AUTISM; BLURRED VISION; COMPULSION; DROWSINESS; DRUG EFFICACY; EXCESSIVE THIRST; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART RHYTHM DISTURBANCE; HUMAN; HYPERACTIVITY; HYPOTHYROIDISM; IRRITABILITY; LIVER TOXICITY; NAUSEA; PANCREATITIS; PARENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; SKIN ALLERGY; TREMOR; WEIGHT GAIN;

CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; HUMANS; PARENTS; PSYCHOTROPIC DRUGS;

EID: 84863867723     PISSN: 01623257     EISSN: 15733432     Source Type: Journal    
DOI: 10.1007/s10803-010-1144-2     Document Type: Article

References (15)

1. Aman, M. G., McDougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., Wagner, A. (2009). Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. Journal of American Academy of Child and Adolescent Psychiatry.
2. Belsito, K. M., Law, P. A., Kirk, K. S., Landa, R. J., & Zimmerman, A. W. (2001). Lamotrigine therapy for autistic disorder: A randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders, 31(2), 175-181. (Pubitemid 37490163)
3. Correll, C. U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J. M., & Malhotra, A. K. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. Journal of American Medical Association, 302(16), 1765-1773.
4. Hellings, J. A., Weckbaugh, M., Nickel, E. J., Cain, S. E., Zarcone, J. R., Reese, R. M., et al. (2005). A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 15(4), 682-692. (Pubitemid 41434372)
5. Hollander, E., Chaplin, W., Soorya, L., Wasserman, S., Novotny, S., Rusoff, J., Anagnostou, E. (2009). Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology. Advance online publication, December 9, 2009.
6. King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., et al. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Archives of General Psychiatry, 66(6), 583-590.
7. Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of American Academy of Child and Adolescent Psychiatry, 48(11), 1110-1119.
8. McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., et al. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347(5), 314-321. (Pubitemid 34815353)
9. McDougle, C. J., Stigler, K. A., & Posey, D. J. (2003). Treatment of aggression in children and adolescents with autism and conduct disorder. Journal of Clinical Psychiatry, 64(Suppl 4), 16-25. (Pubitemid 36418559)
10. Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., et al. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatricsm, 124(6), 1533-1540.
11. Research Units on Pediatric Psychopharmacology Autism Network. (2005). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62(11), 1266-1274.
12. Scahill, L., Aman, M. G., McDougle, C. J., McCracken, J. T., Tierney, E., Dziura, J., et al. (2006). A prospective open trial of guanfacine in children with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16(5), 589-598. (Pubitemid 44737213)
13. Singh, J., Illes, J., Lazzeroni, L., & Hallmayer, J. (2009). Trends in US autism research funding. Journal of Autism and Developmental Disorders, 39(5), 788-795.
14. Stigler, K. A., Desmond, L. A., Posey, D. J., Wiegand, R. E., & McDougle, C. J. (2004). A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 14, 49-56. (Pubitemid 38525953)
15. Williams, K. W., Wray, J. J., & Wheeler, D. M. (2005). Intravenous secretion for autism spectrum disorder. Cochrane Database Systematic Reviews, 3, CD003495.